Results 51 to 60 of about 3,861 (173)
Saudi Journal of Kidney Diseases and Transplantation, 2012 Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders.
Farrokhlagha Ahmadi +3 more
doaj +1 more source
PLoS ONE, 2013 p-Cresol is a by-product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria. In patients with chronic kidney disease, the accumulation of p-cresol and of its metabolite p-cresyl-sulphate causes endothelial dysfunction and ...
Bruna Guida +10 more
doaj +1 more source
, 2010 Background. Cardiovascular morbidity and mortality are massively increased in patients with chronic kidney disease (CKD). Sevelamer hydrochloride has been shown to attenuate cardiovascular calcifications in CKD and end-stage renal disease (ESRD) patients.
Busch, Birgit +12 more
core +1 more source
Physiological Reports, Volume 14, Issue 9, May 2026.Abstract Chronic volume overload is a major risk factor of hypertension and mortality in chronic dialysis patients. However, the mechanisms responsible for hypertension are unclear. We studied 32 patients (age 23–68 years, 19 females) in chronic hemodiafiltration classified by their interdialytic ambulatory blood pressure (idABP, mmHg) in three groups:
Adolfo Diaz +5 more
wiley +1 more source
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, Volume 36, Issue 1, 2 January 2026.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
A STUDY ON HYPERPHOSPHATEMIA AND EFFECT OF SEVELAMER ON CARDIAC ENZYME LEVELS IN CHRONIC KIDNEY DISEASE PATIENTS [PDF]
, 2016 Objective: Chronic Kidney Disease (CKD) is characterized by progressive loss of kidney function over a period of time. Sevelamer hydrochloride is a phosphate binding agent used to control serum phosphate levels in End Stage Renal Disease (ESRD) patients ...
S., Senthil Kumar, K., Dhivya
core +1 more source
International Journal of Nephrology and Renovascular Disease, 2014 Moustafa Moustafa,1 Lawrence Lehrner,2 Fahd Al-Saghir,3 Mark Smith,4 Sunita Goyal,5 Maureen Dillon,5 John Hunter,5 Randy Holmes-Farley5 1South Carolina Nephrology and Hypertension Center Inc., Orangeburg, SC, USA; 2Kidney Specialists of Southern Nevada ...
Moustafa M +7 more
doaj
Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan +6 more
wiley +1 more source
Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi [PDF]
, 2004 Dialysis-associated hyperphosphatemia has been treated with chelating calcium salts, in particular with calcium carbonate. A new option for the management of this problem is represented by sevelamer, a chelating agent which contains no calcium and no ...
Barbone, Gaia Santagostino +2 more
core +1 more source
Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study [PDF]
, 2020 Hyperphosphatemia is a risk factor for vascular calcifications (VCs), which are part of the chronic kidney disease-mineral and bone disorders (CKD-MBD).
Sandro Giannini +95 more
core +1 more source